Table 1.
Characteristics of the PLWH (n = 138) and HNCs (n = 35) in Wuhan, China, 2021
| Characteristics | PLWH (n = 138) | HNCs (n = 35) | Statistics | P |
|---|---|---|---|---|
| Age in years, median (IQR) | 38 (31–49) | 33 (29–44) | 2.56 | 0.08 |
| Men, No. (%) | 16 (88.4) | 17 (48.6) | 28.06 | < 0.001 |
| Comorbidities (%) | 17 (12.3) | 2 (5.7) | – | 0.26 |
| CD4 cell count/μL, median (IQR) | 495 (320–646) | 666 (534–800) | 4.12 | < 0.001 |
| CD4 cell count (/μL) | ||||
| < 200 | 18 | 0 | ||
| 200–500 | 52 | 4 | ||
| ≥ 500 | 68 | 31 | 18.04 | < 0.001 |
| Receiving ART, n (%) | 126 (91.3) | – | ||
| ART regimens | ||||
| No | 12 (8.7) | – | ||
| NNRTIs (NVP/EFV) | 102 (73.9) | – | ||
| INSTIs (EVG/DTG) | 14 (10.1) | – | ||
| PIs (LPV/r) | 10 (7.3) | – | ||
| HIV VL < 50 copies/mL | 107 (77.5) | |||
| IgM, n (%) | 5 (3.6) | 1 (2.9) | –* | 1.00 |
| IgG,n (%) | 62 (44.9) | 21 (60.0) | 0.11 | |
| nAbs,n (%) | 40 (29.0) | 17 (48.6) | 4.85 | 0.03 |
| IgM titers, GMT (95% CI) | 0.016 (0.014–0.020) | 0.018 (0.013–0.024) | 1.18 | 0.24 |
| IgG titers, GMT (95% CI) | 0.10 (0.074–0.13) | 0.21 (0.14–0.32) | 1.97 | 0.049 |
| Log10 nAbs titers, median (IQR) | 0.57 (0.30–1.11) | 0.91 (0.64–1.26) | 2.46 | 0.01 |
NNRTIs: nonnucleoside reverse transcriptase inhibitors; INSTIs: integrase inhibitors; PIs: protein inhibitors; NVP: nevirapine; EFV: efavirenz; EVG: elvitegravir; DTG: dolutegravir; LPV/r: lopinavir/ritonavir
*No statistics are computed because Fisher exact method was used